Patient considerations in the management of gout and role of combination treatment with lesinurad

Liza W Claus
Joseph J Saseen
Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA

Abstract: Gouty arthritis is one of the most common rheumatic diseases, and the prevalence continues to rise, which is likely related to increased incidence of comorbidities, lifestyle factors, and suboptimal utilization of urate-lowering therapy. In recent years, multiple new guidelines have been published along with the approval of novel drug therapies. Still, gout remains a poorly controlled disease state that is accompanied by a reduced health-related quality of life, increased health care utilization, and overall negative socioeconomic effects, all of which have a negative impact on patient-related health outcomes. The key to success in gout management is utilization of urate-lowering therapy to prevent recurrence of acute gouty arthritis and to resolve tophi, if present. Xanthine oxidase inhibitors are first-line medications for the prevention of recurrent gout followed by uricosurics, including lesinurad (a uric acid reabsorption inhibitor) as an add-on option. The recent US Food and Drug Administration Safety Communication related to cardiovascular risk with febuxostat may result in increased use of allopurinol in combination therapy with a uricosuric agent such as lesinurad. In this review, we discuss gout management, clinical end points, and patient-related outcomes for consideration, summarize the evidence for combination therapy to achieve serum urate targets, and focus on lesinurad as a novel newer medication for the prevention of gout.

Keywords: gouty arthritis, patient-centered, treatment, lesinurad

Introduction

Gout is the most common inflammatory arthritis among adults in the USA, and its prevalence is increasing in Western countries. Gout is a broad term used to define a spectrum of disease related to excess uric acid secondary to either overproduction or under excretion of serum urate. Persistently elevated uric acid can lead to gouty arthritis, deposition of palpable urate crystals in joints known as tophi, interstitial nephropathy, uric acid nephrolithiasis, and chronic kidney disease (CKD). Elevated uric acid is generally recognized as serum urate of >7 mg/dL. The serum urate goal of therapy for patients diagnosed with gout is <6 mg/dL with an optional <5 mg/dL in some patients and often requires the use of urate-lowering therapy (ULT). However, because acute gouty arthritis may rarely persist despite normal uric acid levels, therapy might also be guided with the goal of avoiding acute gouty arthritis (treat-to-avoid symptoms).

Acute gouty arthritis is treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), or glucocorticoids. ULT is indicated in patients with recurrent flares, tophi, urate arthropathy, or renal stones. Xanthine oxidase inhibitors (XOIs), allopurinol and febuxostat, are first-line medications and are considered the gold standard for...
the prevention of recurrent gouty arthritis. Uricosurics, specifically probenecid in the USA, is considered a second-line medication for patients intolerant of, or with contraindications to, XOI. Uricosurics may also be used in combination with an XOI. Lesinurad is a new uricosuric medication with a novel mechanism of action and has expanded available options for combination therapy. Pegloticase is an expensive intravenous medication that is reserved for gout refractory to conventional therapy.

Despite the availability of multiple guidelines for the management of gout and the introduction of new medication options, gout remains poorly controlled. Factors that may influence persistent symptoms include the high prevalence of cardiometabolic comorbid conditions, poor adherence to ULT, and suboptimal dosing of prophylactic medications. Furthermore, gout is associated with a reduced health-related quality of life (HRQOL), which is possibly related to therapeutic dietary modifications, associated pain, medication concerns, and more frequent health care utilization. This review discusses patient considerations in optimizing the management of gout and the role of combination therapy, focusing on the newest available agent, lesinurad.

**Patient profiles**

Men are three times more likely to develop gout than women, with black patients most commonly affected. The risk of gout increases with age and is especially evident in men older than 30 years and postmenopausal women. Common comorbidities include obesity, hypertension, CKD stage ≥2, diabetes, myocardial infarction, heart failure, and stroke.

A number of dietary factors can influence gout and act as a “trigger” for acute gouty arthritis. Confirmed offenders include excessive consumption of meat, seafood, beer, and liquor. Dietary modifications alone are likely inadequate to treat most patients diagnosed with gout. However, patients with gout should be advised to avoid or limit consumption of alcohol, particularly beer and spirits, sugar-sweetened beverages, meat, and seafood. In contrast, low-fat dairy products, coffee, and cherries have been negatively associated with gout and consumption can be encouraged. An overall healthy diet, routine exercise, and weight loss, if appropriate, should also be advised due to the strong correlation of gout with concomitant cardiometabolic disease and obesity.

Many patients with gout can be characterized as having poor adherence to treatment. Multiple studies have found that fewer than 50% of patients are adherent to medication for gout, with some evidence suggesting that nonadherence may be more common in gout than in other chronic disease. This is particularly true of ULT for the prevention of recurrent gouty arthritis. Lack of education pertaining to the duration of therapy and causes of flares, an awareness that medications may transiently worsen gout symptoms, potential side effect concerns, financial barriers, and an overall disconnect between patients’ and providers’ views on gout are patient factors that may negatively influence adherence.

**Clinical end points and patient-related outcomes**

The desired clinical outcomes in gout are to prevent and ultimately eliminate acute gouty arthritis, dissolve tophi, and prevent chronic arthropathy. The 2012 American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) guidelines, along with the 3e recommendations in rheumatology, endorse a treat-to-target approach to facilitate achievement of clinical outcomes. The widely accepted serum urate target level is <6 mg/dL. However, a lower serum urate target of <5 mg/dL is a consideration for patients with severe gout who need fast dissolution of serum urate crystals, characterized by the presence of tophi or chronic arthropathy, or for certain patients with very frequent attacks. Conversely, the 2017 American College of Physicians (ACP) clinical practice guidelines on the management of acute and recurrent gout does not recommend a serum urate target. The ACP guidelines cite that there is insufficient evidence to conclude whether the benefits of a treat-to-target approach outweigh the harms associated with repeated serum urate monitoring and medication escalation. The ACP guidelines propose a “treat-to-avoid symptoms” approach with a goal of avoiding recurrent acute gouty arthritis but without monitoring of serum urate values.

Differences in guideline recommendations regarding the prevention of gouty arthritis have prompted criticism from some experts in the field. The majority of randomized controlled trials (RCTs) have been developed with a serum urate target as the primary end point, rather than patient-centered clinical outcomes, such as prevention of acute gouty arthritis attacks. This is, in part, due to the short duration of these studies where the incidence of acute gouty arthritis is overall low. In addition, acute gouty arthritis may be temporarily increased following initiation or dose escalation of ULT due to remodeling of tissue urate deposits. For these reasons, reduction in the number of acute gouty arthritis attacks is not an ideal primary end point in studies designed to secure the US Food and Drug Administration (FDA) approval. However, open-label extension studies of allopurinol and febuxostat lasting greater than 1 year demonstrated near
elimination of gout flares and improved tophus status in the majority of patients.16,17 Furthermore, clinical trials evaluating pegloticase, a recombinant pegylated uric acid-specific enzyme that consists of uricase and rapidly and profoundly reduces serum urate in severe gout, provide further evidence that the reduction in serum urate levels to target values correlates with clinical outcomes.18,19

Patient-related outcomes associated with gout therapy should be a high priority in clinical trials. There is ample evidence to support an association between the occurrence of gout and a poor HRQOL, but gout-specific patient-related outcomes that contribute to poor HRQOL are not well defined.20 One small cohort study identified severe joint pain as the cardinal symptom of gout, accompanied by swelling, redness, heat, sensitivity to touch, and stiffness.21 In this study, patients correlated these symptoms with a negative impact on physical functioning, sleep, daily activities, and work. Additional evidence evaluating the benefits of pegloticase in refractory gout further supports that achieving a target serum urate is associated with a positive impact on patient-related outcomes, improving patient assessment of disease activity, pain, physical function, and HRQOL.22 Response to ULT should include both achievement of target serum urate values and patient-reported symptoms, including the impact on daily life and function.

ULT

The pathophysiology of gout is well understood. When serum urate levels reach a point above the saturation threshold (>6.8 mg/dL at pH 7.0 and temperature of 37°C, and >6.0 mg/dL at pH 7.0 and a temperature of 35°C) monosodium urate (MSU) crystals can form.23,24 Reducing serum urate concentrations below the saturation point facilitates the dissolution of MSU crystals and, thus, eventual resolution of gouty arthritis symptoms. Therefore, the use of ULT is the cornerstone of gout management. Recommendations related to the timing of initiation of ULT vary slightly between guidelines and are outlined in Table 1.

The dissolution and mobilization of MSU crystals followed by the initiation or dose titration of ULT can result in increased acute gout symptoms. Acute gout prophylaxis with daily colchicine or low-dose NSAIDs in the presence

---

Table 1 Guideline recommendations for ULT

<table>
<thead>
<tr>
<th>Guideline (year)</th>
<th>Recommendation for ULT</th>
<th>XOI therapies</th>
<th>Combination therapy</th>
</tr>
</thead>
</table>
| ACR (2012)       | Any patient with an established diagnosis of gouty arthritis:  
|                  | • Tophus or tophi on clinical examination or imaging study  
|                  | • Frequent attacks of acute gouty arthritis (≥2 attacks/year)  
|                  | • CKD stage 2 or worse  
|                  | • Past urolithiasis | Allopurinol or febuxostat as first line  
|                  | Febuxostat can be substituted for allopurinol or vice versa in the event of drug intolerance and adverse events, and such a substitution should be considered after initial failure of upward dose titration of one XOI | The addition of a uricosuric agent to an XOI drug or vice versa is an effective option |
| 3e (2014)        | Not specifically addressed | Allopurinol should be used first line. Low to medium doses of febuxostat (40–120 mg) are alternatives in the presence of intolerance or nonresponsiveness to allopurinol | Not specifically addressed |
| EULAR (2017)     | Should be considered and discussed with every patient with a definite diagnosis of gout after the first presentation. Recommended in all patients with recurrent flares, tophi, urate arthropathy, and/or renal stones. Initiation is recommended close to the time of first diagnosis in patients presenting at a young age (<40 years) or with a very high serum urate (8.0 mg/dL) and/or comorbidities (renal impairment, hypertension, ischemic heart disease, heart failure) | Allopurinol as first line in patients with normal kidney function. If the serum urate target cannot be reached by an appropriate dose of allopurinol (or for intolerance), switch to febuxostat | XOI, particularly allopurinol, in combination with a uricosuric is encouraged when serum urate target is not achieved or if symptoms persist on monotherapy |
| ACP (2017)       | Should not be initiated in most patients after a first gout attack or in patients with infrequent attacks. Clinicians should discuss benefits, harms, costs, and individual preferences with patients before initiating, including concomitant prophylaxis, in patients with recurrent gout attacks | Febuxostat (40 mg/day) and allopurinol (300 mg/day) are equally effective at decreasing serum urate levels | Not specifically addressed |

Abbreviations: ACP, American College of Physicians; ACR, American College of Rheumatology; CKD, chronic kidney disease; 3e, Evidence, Expertise, Exchange Initiative; EULAR, European League Against Rheumatism; ULT, urate-lowering therapy; XOI, xanthine oxidase inhibitor.
of a colchicine contraindication or intolerance should be initiated with ULT and continued during the first 6 months of treatment.\(^3\)

**XOIs**

Guidelines emphasize that XOI monotherapy, either with allopurinol or febuxostat, is the first-line therapy for the prevention of gout (Table 1). While guidelines do not typically recommend one XOI over the other, allopurinol is more commonly prescribed, likely due to its generic availability and overall cost effectiveness.\(^25\) In head-to-head and real-life comparisons of allopurinol with febuxostat, attainment of serum urate targets was significantly higher with febuxostat.\(^26,27\) Importantly, a limitation of these data is suboptimal dosing of allopurinol secondary to the lack of further dose escalation by health care providers. In the head-to-head comparison, 300 mg/day of allopurinol was used, and in the real-life comparison the average allopurinol dose was 184.9 mg/day. With the usual dose of allopurinol of 300 mg/day, the achievement of serum urate targets is less than 50% in controlled trials.\(^1\) This is clearly less than desirable. Success rates markedly improve when the allopurinol dose is escalated above this typical dose (much higher than 300 mg/day).\(^28,29\)

The reasons for a conservative allopurinol dosing approach (using no more than 300 mg/day) may be related to product labeling dose restrictions in renal impairment and concern for severe side effects such as allopurinol hypersensitivity syndrome (AHS) which is rare, but potentially life-threatening. While these safety concerns should be considered prior to the initiation of allopurinol, dose escalation beyond 300 mg/day has been proven to be safe.\(^29,30\)

To reduce the risk of AHS, starting doses should not be greater than 100 mg/day for any patient and 50 mg/day for patients with stage 4 or worse CKD. Gradual titration every 2–5 weeks is advised so that doses >300 mg/day can be used in patients with renal impairment if accompanied by adequate patient education and monitoring. Prior to the initiation of allopurinol, HLA-B*5801 allele testing should be obtained for patients of Han Chinese and Thai descent and should be considered in Koreans and patients with stage 3 or worse CKD.\(^1\) Allopurinol should be avoided in patients testing positive for this allele due to a higher risk of AHS.

Febuxostat does not require renal dose adjustment and use of this medication does not have the same risk for hypersensitivity reactions as allopurinol. However, caution should be used prior to prescribing following the 2017 FDA Safety Communication. Preliminary results from a safety trial demonstrated increased cardiovascular death when febuxostat was compared to allopurinol.\(^31\) The trial was designed to compare rates of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and unstable angina requiring urgent coronary revascularization between febuxostat 40–80 mg daily and allopurinol 200–600 mg daily over a period up to 60 months.\(^32\) The primary end point of composite cardiovascular events was not significantly greater in the febuxostat group. However, when the outcomes were evaluated individually, febuxostat showed higher rates of cardiovascular-related death and death from all causes. The FDA will evaluate the final results from the manufacturer when available.\(^31\) These data do not suggest that complete avoidance or immediate discontinuation of febuxostat is necessary. Rather, health care providers should evaluate patient specific cardiovascular risk versus benefits of febuxostat therapy. When not contraindicated, allopurinol may be preferred.

**Uricosurics**

Uricosurics should be used as add-on agents to an XOI when serum urate target is not achieved or if acute gouty arthritis symptoms persist with monotherapy. Uricosurics may be an option as monotherapy in the presence of intolerable adverse effects or contraindications to XOIs. While probenecid is the only available uricosuric approved for gout in the USA and Australia, benzbromarone is an additional agent available in other countries, notably throughout Europe. Benzbromarone is more effective in achieving serum urate target compared to probenecid but may also have a higher risk of hepatotoxicity. Both probenecid and benzbromarone in combination with allopurinol are more effective than allopurinol monotherapy. Overall, high-quality evidence evaluating benzbromarone and probenecid in the reduction in the frequency of gouty arthritis attacks and patient-related outcomes is lacking.\(^33\) However, the use of these medications is very limited in practice. Other medications such as losartan and fenofibrate have uricosuric effects but are not approved by the FDA for the prevention of gout.

**Lesinurad**

Lesinurad was approved by the FDA and European Commission (EC) in 2015. It is available alone as the brand name Zurampic\(^\text{®}\) (Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA) and in combination with allopurinol 200 mg or 300 mg under the brand name Duzallo\(^\text{®}\) (Ironwood Pharmaceuticals, Inc.). Lesinurad has a novel mechanism of action where it decreases serum urate by inhibiting the function...
of transporter proteins (URAT1, OAT4) that reabsorb uric acid in the kidney. URAT1 is responsible for the majority of uric acid reabsorption from the renal tubular lumen, where OAT4 is the transporter involved in diuretic-induced hyperuricemia. Lesinurad is approved by the FDA for use in combination with an XOI for gout; it is not approved for monotherapy.

Combining Lesinurad with Allopurinol Standard of Care in Inadequate Responders (CLEAR) was a two-replicate Phase III trial that provided the requisite data needed for FDA approval. The CLEAR-1 was conducted in the USA, and the CLEAR-2 was conducted in Europe, North America, South Africa, Australia, and New Zealand.\(^3^4,3^5\) In each of these randomized, double-blind trials, patients taking ≥300 mg of allopurinol (≥200 mg in patients with moderate renal impairment) with a baseline serum urate of ≥6.5 mg/dL and ≥2 flares in the previous 12 months were randomized to lesinurad 200 mg, lesinurad 400 mg, or placebo daily. Acute gout prophylaxis was also initiated using daily colchicine or an NSAID in the presence of a colchicine intolerance or contraindication. The primary efficacy end point was the proportion of patients with a serum urate of <6 mg/dL by month 6. Key secondary end points included the mean rate of gout flares requiring treatment from the end of month 6 and month 12 and the proportion of patients with tophi at baseline who experienced complete resolution of one or more tophus at month 12. Safety assessments included treatment-emergent adverse events (TEAEs), laboratory data, physical examination findings, electrocardiogram findings, and vital signs, with renal and cardiovascular safety being the primary focus.

Results of both the CLEAR-1 and CLEAR-2 demonstrated the efficacy of lesinurad. Patients (n=603 in CLEAR-1; n=610 in CLEAR-2) were predominantly men with a mean age of 51 years, gout duration of 11 years, and baseline serum urate of 6.9 mg/dL, and the majority were taking allopurinol 300 mg daily. Lesinurad at doses of 200 mg or 400 mg added to allopurinol significantly increased the proportion of patients who achieved serum urate target of <6 mg/dL when compared to patients receiving allopurinol alone (54.2%, 59.2%, and 27.9%, \(P<0.0001\): CLEAR-1; 55.4%, 66.5%, and 23.3%, \(P<0.0001\): CLEAR-2). There were no differences in secondary outcomes of gout flares requiring treatment or tophus size, although the short duration of the study may contribute to the lack of positive findings. Lesinurad was generally well tolerated. Lesinurad 200 mg had a comparable safety profile to placebo (Table 2), with the exception of renal-related adverse events. Serum creatinine elevations ≥1.5× and ≥2× baseline occurred more commonly in patients taking lesinurad, and this increase was dose dependent (occurring more frequently with lesinurad 400 mg). The

### Table 2 Safety data from lesinurad Phase III clinical trials

<table>
<thead>
<tr>
<th>AE category</th>
<th>CLEAR-1(^a)</th>
<th>CLEAR-2(^a)</th>
<th>CRYSTAL(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo + allopurinol (n=201)</td>
<td>Lesinurad 200 mg + allopurinol (n=201)</td>
<td>Lesinurad 400 mg + allopurinol (n=201)</td>
</tr>
<tr>
<td>Any TEAE (%)</td>
<td>138 (68.7)</td>
<td>147 (73.1)</td>
<td>156 (77.6)</td>
</tr>
<tr>
<td>Any TEAE possibly related to the study drug (%)</td>
<td>19 (9.5)</td>
<td>33 (16.4)</td>
<td>41 (20.4)</td>
</tr>
<tr>
<td>Any serious TEAE (%)</td>
<td>11 (5.5)</td>
<td>9 (4.5)</td>
<td>16 (8.0)</td>
</tr>
<tr>
<td>Any fatal TEAE (%)</td>
<td>0</td>
<td>1 (0.5)</td>
<td>0</td>
</tr>
<tr>
<td>Renal-related AE(^b) (%)</td>
<td>7 (3.5)</td>
<td>8 (4.0)</td>
<td>20 (10.0)</td>
</tr>
<tr>
<td>CV-related AE(^c) (%)</td>
<td>7 (3.5)</td>
<td>9 (4.5)</td>
<td>8 (4.0)</td>
</tr>
</tbody>
</table>

Notes: \(\text{Renal-related AE}\)s reported as TEAEs in CLEAR-1 and CLEAR-2; reported as cumulative AEs in CRYSTAL. \(^a\)The most common renal-related AE\(s\) included increased blood creatinine, increased blood urea nitrogen, renal failure, and kidney stones.

Abbreviations: AE, adverse event; CV, cardiovascular; TEAE, treatment-emergent adverse event.

---

\(^{34}\) SOUTH AFRICA, AUSTRALIA, AND NEW ZEALAND. In each of these randomized, double-blind trials, patients taking ≥300 mg of allopurinol (≥200 mg in patients with moderate renal impairment) with a baseline serum urate of ≥6.5 mg/dL and ≥2 flares in the previous 12 months were randomized to lesinurad 200 mg, lesinurad 400 mg, or placebo daily. Acute gout prophylaxis was also initiated using daily colchicine or an NSAID in the presence of a colchicine intolerance or contraindication. The primary efficacy end point was the proportion of patients with a serum urate of <6 mg/dL by month 6. Key secondary end points included the mean rate of gout flares requiring treatment from the end of month 6 and month 12 and the proportion of patients with tophi at baseline who experienced complete resolution of one or more tophus at month 12. Safety assessments included treatment-emergent adverse events (TEAEs), laboratory data, physical examination findings, electrocardiogram findings, and vital signs, with renal and cardiovascular safety being the primary focus.

Results of both the CLEAR-1 and CLEAR-2 demonstrated the efficacy of lesinurad. Patients (n=603 in CLEAR-1; n=610 in CLEAR-2) were predominantly men with a mean age of 51 years, gout duration of 11 years, and baseline serum urate of 6.9 mg/dL, and the majority were taking allopurinol 300 mg daily. Lesinurad at doses of 200 mg or 400 mg added to allopurinol significantly increased the proportion of patients who achieved serum urate target of <6 mg/dL when compared to patients receiving allopurinol alone (54.2%, 59.2%, and 27.9%, \(P<0.0001\): CLEAR-1; 55.4%, 66.5%, and 23.3%, \(P<0.0001\): CLEAR-2). There were no differences in secondary outcomes of gout flares requiring treatment or tophus size, although the short duration of the study may contribute to the lack of positive findings. Lesinurad was generally well tolerated. Lesinurad 200 mg had a comparable safety profile to placebo (Table 2), with the exception of renal-related adverse events. Serum creatinine elevations ≥1.5× and ≥2× baseline occurred more commonly in patients taking lesinurad, and this increase was dose dependent (occurring more frequently with lesinurad 400 mg). The
majority of these cases were transient and reversible with resolution in approximately two-thirds of patients without interruption of lesinurad. Other adverse effects noted across the two studies included upper respiratory tract infections.34,35

The Combination Treatment Study in Subjects with Subcutaneous Tophaceous Gout with Lesinurad and Febuxostat (CRYSTAL) trial was a Phase III, multinational trial that investigated the safety and efficacy of lesinurad in combination with febuxostat in patients with tophaceous gout.36 Patients with a baseline serum urate of ≥8 mg/dL (≥6 mg/dL with ULT) and ≥1 measurable tophus who were treated with febuxostat 80 mg daily for 3 weeks were included in this trial. They were then randomized to lesinurad 200 mg, lesinurad 400 mg, or placebo daily in addition to febuxostat. Acute gout prophylaxis was initiated concomitantly with febuxostat in the form of daily colchicine or an NSAID in the presence of a colchicine intolerance or contraindication. The primary efficacy end point was the achievement of a serum urate value of <5 mg/dL after 6 months. The key secondary end point was the achievement of a complete resolution of ≥1 tophus after 12 months. Safety assessments included TEAEs, laboratory data, physical examination findings, electrocardiogram results, and vital signs, with renal and cardiovascular safety being the primary focus.

Patients in CRYSTAL (n=324) were predominantly white men with a mean age of 54 years, gout duration of 15 years, baseline serum urate of 8.7 mg/dL, and serum urate of 5.3 mg/dL following 3 weeks of febuxostat. Lesinurad 400 mg added to febuxostat significantly increased the proportion of patients who achieved serum urate target of <5 mg/dL after 6 months when compared to patients receiving febuxostat alone (76.1%, 46.8%, respectively; P<0.0001). Lesinurad 200 mg added to febuxostat did not significantly increase the proportion of patients achieving serum urate target after 6 months but did at all other time points. There was no difference between the number of patients with complete tophus resolution. However, lesinurad 200 mg and 400 mg added to febuxostat did significantly reduce the total target tophus area when compared to febuxostat alone (50.1%, 52.9%, 28.3%, respectively; P<0.05).

Lesinurad was generally well tolerated in the CRYSTAL study (Table 2). The proportion of patients with TEAEs throughout the study was 72.5% in the febuxostat alone group, 82.1% with lesinurad 200 mg plus febuxostat and 82.6% with lesinurad 400 mg plus febuxostat. Serum creatinine elevations ≥1.5× baseline occurred in 2.8% (n=3), 4.7% (n=5), and 10.1% (n=11) of patients in the febuxostat alone, lesinurad 200 mg plus febuxostat, and lesinurad 400 mg plus febuxostat groups, respectively. Of these, 100%, 60%, and 85.7% resolved without interruption of the study drug. Serum creatinine elevations ≥2× baseline occurred in 0%, 2.8% (n=3), and 5.5% (n=6) of the respective groups. Only one patient in each of the lesinurad plus febuxostat groups had unresolved serum creatinine elevations at the last study assessment. Other individual adverse effects noted were nasopharyngitis, hypertension, headache, extremity pain, and back pain.36

Lesinurad should never be used as monotherapy in patients with gout. In one study comparing lesinurad 400 mg daily to placebo, there was a high incidence of serum creatinine elevations and renal-related adverse events, including kidney stones, renal failure, and acute renal failure.37 When lesinurad is used in the absence of an XOI, the rate of urinary uric acid excretion is higher and has the potential to induce uric acid microcrystallization in the renal tubules, resulting in renal-related adverse effects. Thus, lesinurad is not approved by the FDA for use as monotherapy.

Based on the findings of these studies, lesinurad is only available in the 200 mg dose and has a black-boxed warning that provides safety information related to acute renal failure.38 With approval, the FDA and EC mandated postmarketing studies to more fully evaluate renal and cardiovascular safety of this novel agent.

Lesinurad: role in therapy

Currently, no studies have evaluated lesinurad’s effect on patient-related outcomes such as pain, physical function, and impact on daily life. However, evidence with other available medications has correlated achievement of serum urate targets with improvements in clinical outcomes and patient-related outcomes. Presumably, this should be true with lesinurad. However, because lesinurad has a unique mechanism of action, this cannot be assumed. Because lesinurad is still a relatively new therapy, to date, uptake by health care professionals has not been widespread. According to the manufacturer’s quarterly reports, a total of only 4,466 prescriptions for lesinurad were filled in 2017 through the third quarter.39–41 However, interest in using allopurinol with lesinurad may increase in the wake of the febuxostat FDA Safety Communication and the new availability of a fixed-dose allopurinol/lesinurad combination product in 2017.

While this first step to providing maximum ULT is optimizing the dose of allopurinol up to 800 mg daily to achieve maximum efficacy, lesinurad may be of benefit for selected patients. Patients who do not achieve individualized serum urate target of <6 mg/dL or <5 mg/dL or those with
continued severe gout symptoms (tophi, chronic arthropathy, frequent attacks) on a maximally tolerated XOI would be ideal candidates for lesinurad treatment. Because lesinurad can be used in patients with a creatinine clearance as low as 45 mL/min, it may be particularly useful in patients with moderate CKD where dose titration of allopurinol may be limited. Finally, there is some evidence that dyslipidemia, abdominal obesity, and alcohol consumption are factors that may be associated with a poor response to ULT.42 The presence of these comorbidities may represent another patient population where lesinurad could be considered.

Ultimately, the use of lesinurad should be determined by provider and patient preferences as it relates to risks, benefits, and cost. Patients who are prescribed lesinurad should have a baseline renal function assessment followed by periodic monitoring. Patients prescribed lesinurad should be informed of known side effects and instructed to maintain adequate hydration (clinical trials demonstrating efficacy with lesinurad encouraged a 2 L intake of fluid daily).

Conclusion

Despite a well-understood pathophysiologic mechanism of disease, generally consistent guideline recommendations, and effective treatment options, gout remains a poorly controlled disease. In light of concerning cardiovascular findings with febuxostat, health care providers should optimize the doses of allopurinol to achieve serum urate targets. If additional therapy is warranted, lesinurad is a new medication that, when combined with an XOI, is effective in reaching serum urate targets. Clinical efficacy and improvements in patient-related outcomes have yet to be demonstrated with the use of lesinurad. Clinical studies have not been designed to assess these outcomes as primary end points with lesinurad therapy. Future studies should be of longer duration, include clinical efficacy primary outcomes such as episodes of recurrent gouty arthritis requiring treatment, and ensure that an optimized dose of allopurinol >300 mg daily is utilized.

Disclosure

The authors report no conflicts of interest in this work.

References


